US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

18.91

+0.37002.00%

Post-market: 18.910.00000.00%16:04 EDT

Volume:335.52K

Turnover:6.29M

Market Cap:545.98M

PE:-102.51

High:19.06

Open:18.51

Low:17.89

Close:18.54

Loading ...

Overview Company News Filings

BTIG Reaffirms Their Buy Rating on Castle Biosciences (CSTL)

BRIEF-Castle Biosciences Inc Says FY 2024 Revenue Expected To Exceed $320-330 Million, 50% Growth Over 2023

Castle Biosciences Inc - 2024 Revenue Expected to Exceed $320-330 Million, 50% Growth Over 2023

THOMSON REUTERS

Press Release: Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

Castle Biosciences drops as regional Medicare contractor won’t cover test

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia

CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates

FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief

Here's Why You Should Consider Buying Atara Biotherapeutics Stock

HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Geron Stock Rallies More Than 60% in a Year: Here's Why

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use

AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs

Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?

Castle Biosciences Says TissueCypher Test Approved by New York Health Department

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CSTL/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSTL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","market":"US","secType":"STK","nameCN":"Castle Biosciences, Inc.","latestPrice":18.91,"timestamp":1750276800000,"preClose":18.54,"halted":0,"volume":335521,"hourTrading":{"tag":"盘后","latestPrice":18.91,"preClose":18.91,"latestTime":"16:04 EDT","volume":11026,"amount":208501.66,"timestamp":1750277052166},"delay":0,"floatShares":26464372,"shares":28872315,"eps":-0.184478,"marketStatus":"Closed","change":0.37,"latestTime":"06-18 16:00:00 EDT","open":18.51,"high":19.0625,"low":17.8862,"amount":6294771.903825,"amplitude":0.063447,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.184478,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750406400000},"marketStatusCode":5,"adr":0,"listingDate":1564027200000,"exchange":"NASDAQ","adjPreClose":18.54,"preHourTrading":{"tag":"盘前","latestPrice":18.54,"preClose":18.54,"latestTime":"08:00 EDT","volume":1,"amount":18.54,"timestamp":1750248000927},"postHourTrading":{"tag":"盘后","latestPrice":18.91,"preClose":18.91,"latestTime":"16:04 EDT","volume":11026,"amount":208501.66,"timestamp":1750277052166},"volumeRatio":0.680629,"impliedVol":0.3351,"impliedVolPercentile":0.024},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","floatShares":26464372,"roa":"-1.79%","roe":"-1.20%","lyrEps":0.656862,"volumeRatio":0.680629,"shares":28872315,"dividePrice":0,"high":19.0625,"amplitude":0.063447,"preClose":18.54,"low":17.8862,"week52Low":15.45,"pbRate":"1.24","psRate":"1.57","week52High":35.84,"institutionHeld":0,"latestPrice":18.91,"eps":-0.184478,"divideRate":0,"volume":335521,"delay":0,"ttmEps":-0.184478,"open":18.51,"prevYearClose":26.65,"prevWeekClose":18.75,"prevMonthClose":15.97,"prevQuarterClose":20.02,"fiveDayClose":18.44,"twentyDayClose":16.5,"sixtyDayClose":20.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSTL\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503637180","title":"BTIG Reaffirms Their Buy Rating on Castle Biosciences (CSTL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503637180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503637180?lang=en_us&edition=fundamental","pubTime":"2025-01-13 18:25","pubTimestamp":1736763952,"startTime":"0","endTime":"0","summary":"BTIG analyst Mark Massaro maintained a Buy rating on Castle Biosciences (CSTL – Research Report) today and set a price target of $40.00. The compan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-reaffirms-their-buy-rating-on-castle-biosciences-cstl-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-reaffirms-their-buy-rating-on-castle-biosciences-cstl-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSTL"],"gpt_icon":0},{"id":"2503390959","title":"BRIEF-Castle Biosciences Inc Says FY 2024 Revenue Expected To Exceed $320-330 Million, 50% Growth Over 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2503390959","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503390959?lang=en_us&edition=fundamental","pubTime":"2025-01-13 07:01","pubTimestamp":1736722911,"startTime":"0","endTime":"0","summary":"BRIEF-Castle Biosciences Inc Says FY 2024 Revenue Expected To Exceed $320-330 Million, 50% Growth Over 2023Jan 12 (Reuters) - Castle Biosciences Inc CSTL.O:CASTLE BIOSCIENCES INC - 2024 REVENUE EXPECT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250112:nFWN3O61DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSTL"],"gpt_icon":0},{"id":"2503390953","title":"Castle Biosciences Inc - 2024 Revenue Expected to Exceed $320-330 Million, 50% Growth Over 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2503390953","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503390953?lang=en_us&edition=fundamental","pubTime":"2025-01-13 07:00","pubTimestamp":1736722834,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250112:nFWN3O61DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSTL","BK4196"],"gpt_icon":0},{"id":"2503390656","title":"Press Release: Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2503390656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503390656?lang=en_us&edition=fundamental","pubTime":"2025-01-13 07:00","pubTimestamp":1736722800,"startTime":"0","endTime":"0","summary":"2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023. Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023. Year-end 2024 cash, cash equivalents and marketable investment securities expected to be approximately $293 million. Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2024.\"Our strong fourth quarter performance underscores continued momentum built throughout 2024, reflecting the strength of our growth initiatives and the dedication of our team,\" said Derek Maetzold, president and chief executive officer of Castle Biosciences. \"As a result, we expect to meet or exceed the top end of our full-year 2024 revenue guidance of $320-330 million. This achievement reflects our commitment to delivering value to our stockholders whil","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","R","BK4022","CSTL","BK4232"],"gpt_icon":0},{"id":"2502816855","title":"Castle Biosciences drops as regional Medicare contractor won’t cover test","url":"https://stock-news.laohu8.com/highlight/detail?id=2502816855","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502816855?lang=en_us&edition=fundamental","pubTime":"2025-01-11 02:50","pubTimestamp":1736535032,"startTime":"0","endTime":"0","summary":"Castle Biosciences (CSTL) shares are lower in Friday trading after Novitas, a regional Medicare contractor, finalized its decision to not cover one...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/castle-biosciences-drops-as-regional-medicare-contractor-wont-cover-test?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/castle-biosciences-drops-as-regional-medicare-contractor-wont-cover-test?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2502081025","title":"FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2502081025","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502081025?lang=en_us&edition=fundamental","pubTime":"2025-01-11 02:42","pubTimestamp":1736534520,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that the FDA has notified it about an update to its supplemental new drug application  for cabozantinib.In November 2024, the FDA notified the company that the sNDA for cabozantinib for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors  and advanced extra-pancreatic NET  would be discussed at an Oncologic Drugs Advisory Committee  meeting in March 2025.The FDA has now notified the company that its sNDA will no longer be the subject of discussion at the ODAC meeting. The sNDA is under FDA review and has a target action date of April 3, 2025.Exelixis’ shares have gained 53.2% in the past six months against the industry’s decline of 10.1%.In August 2023, the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board unanimously recommended that enrollment in the CABINET trial be stopped and randomized patients be unblinded to therapy with the allowance for crossover from placebo to cabozantini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-updates-exel-previously-scheduled-184200304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B2B36J28.USD","BK4533","LU0006306889.USD","IMCR","LU2089984988.USD","LU1066051811.HKD","LU1037948897.HKD","LU1291159041.SGD","LU1699723380.USD","EXEL","LU2106854487.HKD","LU1989772840.SGD","LU2361045086.USD","LU0965509010.AUD","LU2112291526.USD","BK4585","LU1571399168.USD","LU0320765489.SGD","PFS","IE000M9KFDE8.USD","LU1934455277.USD","BK4139","SG9999002232.USD","SG9999013999.USD","LU1023059063.AUD","LU1057294990.SGD","IE00BJT1NW94.SGD","BK4516","BK4532","SG9999015358.SGD","DTC","SG9999002224.SGD","IE0002141913.USD","MRK","LU0265550946.USD","RCC","BK4211","IE00BJJMRZ35.SGD","LU1061106388.HKD","CSTL","IE0009355771.USD","LU0058720904.USD","SGXZ57979304.SGD","LU0211331839.USD","LU0985320562.USD","IE00B1BXHZ80.USD","SG9999015341.SGD","LU1093756168.USD","LU0208291251.USD","LU1941712264.USD"],"gpt_icon":0},{"id":"2502520890","title":"SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2502520890","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502520890?lang=en_us&edition=fundamental","pubTime":"2025-01-10 23:16","pubTimestamp":1736522160,"startTime":"0","endTime":"0","summary":"Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results from a potentially groundbreaking type 1 diabetes  study of its experimental cell therapy, UP421.Notably, in the investigator-sponsored, first-in-human study, UP421 was transplanted into a patient with T1D without the use of any immunosuppression. UP421, an allogeneic primary islet cell therapy, is being developed in partnership with Uppsala University Hospital, utilizing Sana’s proprietary hypoimmune  technology.The study results were evaluated four weeks after intramuscular cell transplantation, which confirmed the survival and functionality of pancreatic beta cells in the first treated T1D patient. The results were supported by the presence of circulating C-peptide, a biomarker indicating insulin production by the transplanted beta cells.C-peptide levels further increased during a mixed meal tolerance test, demonstrating insulin secretion in response to a meal. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sana-stock-surges-152-week-151600351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","BK4139","LU0053671581.USD","CTMX","HALO","SANA","CSTL"],"gpt_icon":1},{"id":"2502468898","title":"FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2502468898","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502468898?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:24","pubTimestamp":1736515440,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, its investigational neonatal Fc receptor  blocker, in generalized myasthenia gravis  indication.The filing has been granted priority review by the FDA, bringing down the review period by four months. We expect a final decision in the third quarter of 2025.The FDA filing is supported by data from the phase III Vivacity-MG3 study, which evaluated nipocalimab in adults with gMG, including those with anti-AChR, anti-MuSK and anti-LRP4 positive antibodies. Data from the study showed that patients who received nipocalimab plus standard of care achieved sustained disease controlover 24 weeks compared with those who received placebo plus SOC. A similar regulatory filing for the drug is under review by the EMA, also supported by data from this study.Per J&J, the above results make Vivacity-MG3 the first and only study to achieve sustained disease control in gMG patients wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-j-js-filing-132400420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1162221912.USD","LU0098860793.USD","LU0345769128.USD","BK4213","IE00B1BXHZ80.USD","LU1066051498.USD","LU1244550577.SGD","LU1674673691.USD","IE0034235303.USD","LU1221951046.USD","LU0345770993.USD","IE00BJJMRZ35.SGD","LU1032466523.USD","LU0114720955.EUR","LU1935042991.SGD","IE0009355771.USD","SG9999001440.SGD","LU1894683264.USD","CSTL","LU0889565916.HKD","LU0320765992.SGD","IE00B2B36J28.USD","LU0345770308.USD","LU1057294990.SGD","LU1032955483.USD","LU0058720904.USD","ARGX","CTMX","LU0792757196.USD","LU1280957306.USD","SOC","BK4533","LU0234570918.USD","LU0466842654.USD","SG9999002224.SGD","LU0912757837.SGD","BK4505","LU1066051225.USD","BK4139","BK4550","LU0320765646.SGD","IE00B4R5TH58.HKD","LU1066051811.HKD","IE00BVYPNV92.GBP","JNJ","IE0002270589.USD","LU1261432733.SGD","LU0109394709.USD","LU1732800096.USD","LU0122379950.USD"],"gpt_icon":0},{"id":"2502636025","title":"VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2502636025","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502636025?lang=en_us&edition=fundamental","pubTime":"2025-01-10 00:42","pubTimestamp":1736440920,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. VIR announced encouraging initial data from a phase I study that evaluated its investigational pipeline candidates, VIR-5818 and VIR-5500, for the treatment of various solid tumors.While VIR-5818 is designed to target a variety of HER2-expressing solid tumors, VIR-5500 is designed to target PSMA in metastatic castration-resistant prostate cancer .Initial data from the phase I study demonstrated compelling early clinical response signals for both T-cell engagers , VIR-5818 and VIR-5500, in heavily pretreated patients with various types of solid tumors.Shares of Vir Biotechnology jumped 58.2% on Jan. 8 following the announcement of the news.In the past year, shares of VIR have rallied 21.1% against the industry’s decline of 14.3%.Per the company, VIR-5818 and VIR-5500 leverage the PRO-XTEN masking technology with different TCEs targeting HER2 and PSMA, respectively. The technology is designed to allow the selective activation of TCEs in the tumor microenvironment,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-stock-early-safety-efficacy-164200842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","BK4196","BK4213","CRC","CSTL","PBYI","BK4217","BK4139","BK4585","LU0456854461.SGD","BK4533","LU0266512127.USD","VIR","BK4084","CTMX","BK4535","PSA","BK4588"],"gpt_icon":0},{"id":"2502041401","title":"CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva","url":"https://stock-news.laohu8.com/highlight/detail?id=2502041401","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502041401?lang=en_us&edition=fundamental","pubTime":"2025-01-09 22:53","pubTimestamp":1736434380,"startTime":"0","endTime":"0","summary":"Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor,SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals TEVA regarding the Firdapse  patent litigation.The settlement agreement resolves the patent litigation brought by Catalyst and SERB on Teva for submitting an abbreviated new drug application  to the FDA seeking marketing approval for a generic version ofFirdapse 10 mg tablets before applicable patents expire.Please note that Firdapse is currently approved in the United States, the EU and Japan for the symptomatic treatment ofLambert-Eaton Myasthenic Syndrome  in adults. In 2022, Catalyst received FDA approval for the label expansion of Firdapse in the United States for treating LEMS in pediatric patients . Last year, the FDA approved Catalyst’s regulatory filing to increase the maximum daily dose of Firdapse for adults and pediatric patients over 45 kg from 80 mg to 100 mg for treating LEMS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cprx-stock-rises-17-settling-145300529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HALO","TEVA","BK4566","BK4588","BK4007","LU0053671581.USD","CSTL","CPRX","BK4196","BK4596","BK4584","BK4139","BK4585","BK4559","BK4557"],"gpt_icon":0},{"id":"2502043249","title":"FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2502043249","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502043249?lang=en_us&edition=fundamental","pubTime":"2025-01-09 21:14","pubTimestamp":1736428440,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals AGIO announced that the FDA has accepted its supplemental new drug application  seeking label expansion for its sole marketed drug, Pyrukynd, in thalassemia indication.A final decision is expected by Sep. 7, 2025. If approved, Pyrukynd will become the first oral therapy for use in all thalassemia subtypes. A commercial launch in this indication is expected before this year’s end.The sNDA is supported by data from two phase III studies, ENERGIZE and ENERGIZE-T, which evaluated Pyrukynd for alpha or beta-thalassemia patients who are non-transfusion-dependent and transfusion-dependent, respectively. Both studies achieved their primary and key secondary endpoints. Similar regulatory filings have been submitted by Agios in the European Union, Kingdom of Saudi Arabia and United Arab Emirates, supported by data from the two studies.Pyrukynd is currently approved by the FDA to treat adults with pyruvate kinase deficiency, a rare and debilitating blood disorder. It is the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-agios-snda-pyrukynd-131400406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","RPRX","BK4139","CTMX","AGIO","BK4007","CSTL"],"gpt_icon":0},{"id":"2502073197","title":"CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2502073197","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502073197?lang=en_us&edition=fundamental","pubTime":"2025-01-09 02:36","pubTimestamp":1736361360,"startTime":"0","endTime":"0","summary":"Shares of CorMedix CRMD rose nearly 30% on Tuesday after management announced fourth-quarter and full-year 2024 preliminary sales figures.CorMedix reported preliminary net revenues of nearly $31 million for the fourth quarter of 2024. This unaudited figure significantly beat the Zacks Consensus Estimate of $21.5 million. Based on these figures, management expects adjusted EBITDA for the quarter to exceed $12 million.For the full year, management reported preliminary net revenues of about $43 million, which beat the Zacks Consensus Estimate of $33.8 million. The preliminary unaudited cash and short-term investments, as of 2024-end, totaled around $52 million.These figures were possibly generated entirely from the sale of CorMedix’s sole marketed product, DefenCath, which was approved by the FDA in November 2023 as the first catheter lock solution. The product has been designed to significantly reduce the incidence of catheter-related bloodstream infections in adult patients receiving ch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cormedix-stock-rises-q4-preliminary-183600741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL"],"gpt_icon":0},{"id":"2502709095","title":"FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief","url":"https://stock-news.laohu8.com/highlight/detail?id=2502709095","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502709095?lang=en_us&edition=fundamental","pubTime":"2025-01-09 00:12","pubTimestamp":1736352720,"startTime":"0","endTime":"0","summary":"Pacira BioSciencesPCRX announced that the FDA has cleared its application to market a new Smart Tip for the iovera system designed to access the medial branch nerves to manage chronic low back pain. Please note that this hand-held medical devicewas added to Pacira’s portfolio following the acquisition of MyoScience.The iovera system is a groundbreaking, FDA-approved, drug-free treatment that alleviates pain through cryoneurolysis. This technique uses targeted cold therapy to temporarily disrupt a nerve's ability to transmit pain signals. Patients usually experience immediate pain relief after treatment, with effects lasting for several months as the nerve naturally regenerates.Per the data readout, patients treated with iovera experienced significantly greater pain reduction, with scores more than 2 points lower on the 0-10 NRS Pain scale at 180 and 360 days compared to RFA. After 360 days of treatment, iovera patients experienced statistically and clinically significant improvements i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-clears-pcrxs-iovera-smart-161200175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","BK4196","HALO","LU0053671581.USD","CTMX","BK4139","BK4007","PCRX"],"gpt_icon":0},{"id":"2502706343","title":"Here's Why You Should Consider Buying Atara Biotherapeutics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2502706343","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502706343?lang=en_us&edition=fundamental","pubTime":"2025-01-08 23:44","pubTimestamp":1736351040,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics ATRA is a nimble allogeneic T cell immunotherapy company with several near-term catalysts. This Zacks Rank #2  company boasts a pipeline of differentiated therapies across a range of oncology and autoimmune indications from its proven EBV T cell platform.The company’s biologics license application  seeking approval for its lead product candidate, tabelecleucel , in the United States is under priority review with the FDA. A decision is expected on Jan. 15.EBV+ PTLD is a rare hematologic malignancy  with a high mortality rate and occurs after patients undergo transplantation when their T-cell immune responses are compromised by immunosuppression.Tab-cel is already marketed in the EU under the brand name, Ebvallo, by Atara’s partner Pierre Fabre Medicament under an exclusive commercialization and license agreement. In 2023, Atara expanded its partnership with Pierre Fabre to commercialize tab-cel in the United States and all remaining global markets.In the past 60 da","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-consider-buying-atara-154400873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053671581.USD","HALO","CSTL","BK4139","PBYI","BK4196","ATRA"],"gpt_icon":0},{"id":"2502706615","title":"HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2502706615","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502706615?lang=en_us&edition=fundamental","pubTime":"2025-01-08 23:41","pubTimestamp":1736350860,"startTime":"0","endTime":"0","summary":"Shares of Hoth Therapeutics HOTH skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001, which is being developed to address skin toxicities linked to cancer patients undergoing treatment with EGFR inhibitors.Per the data readout from the ongoing phase IIa study, all patients treated with the candidate achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvement by the six-week mark. Hoth's proprietary ARIGA scale, developed in partnership with onco-dermatology experts, provides an accurate tool for measuring and evaluating improvements in skin toxicity.Additionally, 66% of patients treated withHT-001 reported reduced pain and itching scores, which significantly improved their quality of life. Importantly, all patients retained their full EGFR inhibitor dosage, ensuring the cancer treatment's complete therapeutic efficacy. This is a signific","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hoth-stock-soars-skin-toxicity-154100180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053671581.USD","BK4007","CSTL","CTMX","HOTH","HALO","BK4196","BK4139"],"gpt_icon":1},{"id":"2502513708","title":"Geron Stock Rallies More Than 60% in a Year: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2502513708","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502513708?lang=en_us&edition=fundamental","pubTime":"2025-01-08 23:33","pubTimestamp":1736350380,"startTime":"0","endTime":"0","summary":"For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo for the treatment of low- to intermediate-1 risk myelodysplastic syndromes  with transfusion-dependent anemia in June.Geron’s shares have risen 61.1% in the past year against a decrease of 15.6% for the industry. Here we discuss some reasons for the same.In December, the Committee for Medicinal Products for Human Use  of the European Medicines Agency gave a positive opinion recommending the approval of Rytelo in the EU. The European Commissionis expected to give its decision regarding the approval of Rytelo in the first half of 2025.In the past 60 days, 2024 loss estimates for Geron have improved from 26 cents per share to 25 cents per share. For 2025, loss estimates have improved from 10 cents to 6 cents per share over the same timeframe.In the past 60 days, estimates for Halozyme Therapeutics’ 2025 earnings per share have increased from $4.80 to $4.81. In the past y","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-stock-rallies-more-60-153300239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","PBYI","BK4139","LU0053671581.USD","BK4087","HALO","CHMP","GERN","CSTL"],"gpt_icon":0},{"id":"2501780966","title":"RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2501780966","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501780966?lang=en_us&edition=fundamental","pubTime":"2025-01-07 23:14","pubTimestamp":1736262840,"startTime":"0","endTime":"0","summary":"HOFH is an inherited disease that causes dangerously high levels of low-density lipoprotein cholesterol , or bad cholesterol. It affects approximately 1,600 people in the EU and 1 in 300,000 globally. Please note that Evkeeza was initially approved in the EU in 2021 as an adjunct to diet and other LDL-C-lowering therapies to treat adult and adolescent patients aged 12 years and older with HoFH. The drug’s label was later expanded in 2023 to include the treatment of children aged 5-11 years old with HoFH. The drug is also approved in multiple other geographies for the HoFH indication like the United States, United Kingdom and Canada, among others.In the past three months, shares of Ultragenyx have plunged 20% compared with the industry’s 9.4% decline.More on Evkeeza’s Label Update for Younger HoFH Patients. Ultragenyx’s commercial portfolio comprises three other medicines — Mepsevii , Crysvita  and Dojolvi .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rares-cholesterol-drug-evkeeza-gains-151400355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EC","LU0882574055.USD","LU0114720955.EUR","LU2362541273.HKD","BK4588","LU2023250504.SGD","LU2468319806.SGD","LU2362540622.SGD","LU0320765992.SGD","REGN","LU0109394709.USD","VNDA","LU0053666078.USD","LU1917777945.USD","LU0289739699.SGD","LU2089984988.USD","LU2106854487.HKD","BK4585","LU1974910355.USD","LU2237438978.USD","CSTL","BK4196","RARE","BK4139","BK4201","LU2362541513.USD","LU0823416689.USD","LU0058720904.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2501209643","title":"AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2501209643","media":"Zacks","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501209643?lang=en_us&edition=fundamental","pubTime":"2025-01-07 19:51","pubTimestamp":1736250660,"startTime":"0","endTime":"0","summary":"In an SEC filing, AbbVie ABBV has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per share  by 88 cents due to in-process research and development  expenses incurred for acquisitions and collaborations during the fourth quarter.The adjusted EPS guidance for full-year 2024 was lowered from $10.90-$10.94 to $10.02-$10.06 due to acquisition costs of $1.6 billion on a pre-tax basis. The Zacks Consensus Estimate for this metric is pegged at $10.96.Including the acquired IPR&D and milestone expense, the fourth-quarter adjusted EPS guided range was lowered to $2.06-$2.10 from $2.94-$2.98. The Zacks Consensus Estimate for earnings is pegged at $2.99 per share.The above projection does not impact AbbVie’s previously issued guidance for 2024 revenues, which are expected to be around $56 billion. Sales for the fourth quarter are expected to be roughly $14.8 billion.In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have risen f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-cuts-2024-eps-guidance-115100747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABBV","CSTL"],"gpt_icon":0},{"id":"2501662462","title":"Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2501662462","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501662462?lang=en_us&edition=fundamental","pubTime":"2025-01-07 00:54","pubTimestamp":1736182440,"startTime":"0","endTime":"0","summary":"Vanda Pharmaceuticals Inc. VNDA generates revenues from the sale of its three commercial products, Fanapt, Hetlioz and Ponvory.Fanapt is approved in the United States for two indications, schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. Hetlioz is approved to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome.Ponvory is an oral treatment approved to treat relapsing forms of multiple sclerosis. VNDA acquired the United States and Canada rights to Ponvory from Actelion Pharmaceuticals Limited, a subsidiary of Johnson & Johnson JNJ, in December 2023.JNJ gained approval for Ponvory as an oral treatment for adults with relapsing forms of multiple sclerosis in 2021.In the past year, shares of Vanda have gained 13.9% against the industry’s decline of 16%.In the past 60 days, estimates for Puma Biotechnology’s 2025 earnings per share have increased from 42 cents to 54 cents. In the past year, shares o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/good-idea-invest-vanda-pharmaceuticals-165400674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BSNM7G36.USD","LU0234572021.USD","IE0002270589.USD","IE00BVYPNV92.GBP","IE00B1BXHZ80.USD","ASO","LU0466842654.USD","CSTL","IE000M9KFDE8.USD","LU0882574055.USD","LU0122379950.USD","LU1057294990.SGD","LU1074936037.SGD","LU1732799900.SGD","LU1221951046.USD","BK4568","LU1929549753.HKD","LU2089984988.USD","VNDA","LU1066051811.HKD","LU1674673428.USD","BK4592","LU0889566641.SGD","BK4007","LU1506573853.SGD","IE00BFTCPJ56.SGD","PBYI","IE0009355771.USD","LU1196500208.SGD","SG9999002224.SGD","LU1261432733.SGD","LU1914381329.SGD","BK4533","LU1718418525.SGD","LU0792757196.USD","LU1032466523.USD","LU0203345920.USD","LU2468319806.SGD","LU0320765646.SGD","LU0640476718.USD","BK4581","LU0345769631.USD","LU1059921491.USD","LU0058720904.USD","JNJ","IE00BJJMRZ35.SGD","IE00B3PB1722.GBP","SG9999001440.SGD","LU1430594728.SGD","LU0795875086.SGD"],"gpt_icon":0},{"id":"2501810230","title":"Castle Biosciences Says TissueCypher Test Approved by New York Health Department","url":"https://stock-news.laohu8.com/highlight/detail?id=2501810230","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501810230?lang=en_us&edition=fundamental","pubTime":"2025-01-06 22:23","pubTimestamp":1736173392,"startTime":"0","endTime":"0","summary":"Castle Biosciences  said Monday it has received approval from the New York State Department of Health for its TissueCypher test, a tool designed to assess the risk of progression from Barrett's esophagus to esophageal cancer.The company said the approval expands its New York Clinical Laboratory Permit to include this test, along with others in its dermatology, gastroenterology, and ophthalmology portfolios.Shares of the company were up 4.2% in recent Monday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","CSTL"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":143,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSTL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-05","symbol":"CSTL","fiscalQuarterEnding":"2025/03","expectedEps":-0.08,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746417600000,"reportTimeType":"post","actualEps":-0.2},{"market":"US","date":"2025-02-27","symbol":"CSTL","fiscalQuarterEnding":"2024/12","expectedEps":0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":0.32},{"market":"US","date":"2025-01-12","symbol":"CSTL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736658000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-04","symbol":"CSTL","fiscalQuarterEnding":"2024/09","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730696400000,"reportTimeType":"post","actualEps":0.08},{"market":"US","date":"2024-08-05","symbol":"CSTL","fiscalQuarterEnding":"2024/06","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722830400000,"reportTimeType":"post","actualEps":0.31}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSTL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSTL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5556,"buy":0.4444,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5556,"analysts":9,"updateTime":1702526400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CSTL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CSTL","date":"2025-06-17","current":-109.759225,"percent":0.183442,"low":-703.916349,"twenty":-97.732254,"median":-12.899374,"eighty":-4.847918,"high":155.734424,"avg":-50.599424,"sd":147.336455,"marketCap":556369510},"quantilePoints":[{"date":"2020-06-19","current":101.300632,"twenty":-137.181173,"median":72.096597,"eighty":89.912228,"marketCap":729871056},{"date":"2020-06-26","current":93.605957,"twenty":-130.766504,"median":72.216999,"eighty":90.734693,"marketCap":674430922},{"date":"2020-07-02","current":102.622433,"twenty":-129.220801,"median":72.241079,"eighty":91.444186,"marketCap":739394631},{"date":"2020-07-10","current":111.372149,"twenty":-123.084358,"median":72.843088,"eighty":91.857697,"marketCap":802436336},{"date":"2020-07-17","current":117.305694,"twenty":-115.1504,"median":73.469177,"eighty":92.281742,"marketCap":845187527},{"date":"2020-07-24","current":106.527432,"twenty":-106.40243,"median":74.167508,"eighty":92.916333,"marketCap":767530147},{"date":"2020-07-31","current":105.654256,"twenty":-102.767312,"median":74.396271,"eighty":93.757226,"marketCap":761238917},{"date":"2020-08-07","current":114.058572,"twenty":-101.783309,"median":74.456472,"eighty":94.202941,"marketCap":821792012},{"date":"2020-08-14","current":114.576879,"twenty":-98.400291,"median":74.981827,"eighty":94.738911,"marketCap":813266685},{"date":"2020-08-21","current":126.944083,"twenty":-97.554536,"median":75.780892,"eighty":96.467657,"marketCap":901049101},{"date":"2020-08-28","current":126.334042,"twenty":-95.952482,"median":76.635745,"eighty":97.420065,"marketCap":896719027},{"date":"2020-09-04","current":133.238602,"twenty":-93.309499,"median":76.98491,"eighty":99.303027,"marketCap":945727595},{"date":"2020-09-11","current":134.763705,"twenty":-92.601993,"median":77.514678,"eighty":100.272889,"marketCap":956552781},{"date":"2020-09-18","current":141.52962,"twenty":-91.068613,"median":78.020365,"eighty":102.449512,"marketCap":1004577242},{"date":"2020-09-25","current":137.592079,"twenty":-89.595469,"median":78.419535,"eighty":103.419182,"marketCap":976628580},{"date":"2020-10-02","current":142.611057,"twenty":-88.909949,"median":79.699487,"eighty":106.169125,"marketCap":1012253283},{"date":"2020-10-09","current":152.122158,"twenty":-87.950343,"median":80.235758,"eighty":108.912247,"marketCap":1079763078},{"date":"2020-10-16","current":138.5626,"twenty":-87.36482,"median":81.186932,"eighty":110.294181,"marketCap":983517335},{"date":"2020-10-23","current":143.747953,"twenty":-87.250969,"median":82.192491,"eighty":112.350606,"marketCap":1020322967},{"date":"2020-10-30","current":128.746478,"twenty":-87.169646,"median":82.764196,"eighty":114.265895,"marketCap":913842503},{"date":"2020-11-06","current":143.359744,"twenty":-86.063659,"median":84.023258,"eighty":116.079799,"marketCap":1017567465},{"date":"2020-11-13","current":-300.218351,"twenty":-87.950343,"median":82.764196,"eighty":115.530762,"marketCap":1002729291},{"date":"2020-11-20","current":-286.626257,"twenty":-92.601993,"median":82.192491,"eighty":115.132049,"marketCap":957331698},{"date":"2020-11-27","current":-265.105442,"twenty":-97.570801,"median":81.439776,"eighty":114.888032,"marketCap":885452175},{"date":"2020-12-04","current":-309.99512,"twenty":-109.964358,"median":80.259839,"eighty":114.369556,"marketCap":1035383700},{"date":"2020-12-11","current":-356.136701,"twenty":-134.615305,"median":79.885626,"eighty":113.96642,"marketCap":1189496581},{"date":"2020-12-18","current":-450.787075,"twenty":-141.029974,"median":78.954401,"eighty":113.756623,"marketCap":1505628832},{"date":"2020-12-24","current":-515.732815,"twenty":-143.704042,"median":78.164847,"eighty":113.491008,"marketCap":1722547602},{"date":"2020-12-31","current":-485.646593,"twenty":-146.146252,"median":77.835827,"eighty":112.857956,"marketCap":1622059619},{"date":"2021-01-08","current":-575.760614,"twenty":-151.556214,"median":77.346115,"eighty":112.012372,"marketCap":1923040451},{"date":"2021-01-15","current":-536.200125,"twenty":-153.642914,"median":76.720026,"eighty":111.384472,"marketCap":1790908417},{"date":"2021-01-22","current":-572.578418,"twenty":-155.265902,"median":76.491263,"eighty":111.374614,"marketCap":1912411915},{"date":"2021-01-29","current":-483.332268,"twenty":-167.600615,"median":75.585094,"eighty":110.83863,"marketCap":1614329774},{"date":"2021-02-05","current":-671.081866,"twenty":-169.640943,"median":74.685236,"eighty":110.157158,"marketCap":2241413434},{"date":"2021-02-12","current":-690.970595,"twenty":-171.341217,"median":74.456472,"eighty":109.561717,"marketCap":2307841788},{"date":"2021-02-19","current":-656.255723,"twenty":-173.845257,"median":74.33607,"eighty":109.348881,"marketCap":2191894116},{"date":"2021-02-26","current":-550.230719,"twenty":-178.868792,"median":74.167508,"eighty":109.144161,"marketCap":1837770601},{"date":"2021-03-05","current":-498.881637,"twenty":-200.184042,"median":73.01165,"eighty":108.912247,"marketCap":1666264669},{"date":"2021-03-12","current":-155.908697,"twenty":-197.741831,"median":72.590244,"eighty":108.442961,"marketCap":1603365036},{"date":"2021-03-19","current":-161.592235,"twenty":-187.710216,"median":72.241079,"eighty":107.618901,"marketCap":1661814548},{"date":"2021-03-26","current":-145.658896,"twenty":-181.094605,"median":72.144757,"eighty":106.811214,"marketCap":1497956087},{"date":"2021-04-01","current":-172.643561,"twenty":-179.425246,"median":72.072517,"eighty":106.28856,"marketCap":1775466377},{"date":"2021-04-09","current":-168.830246,"twenty":-179.507526,"median":71.807633,"eighty":105.852599,"marketCap":1736250252},{"date":"2021-04-16","current":-159.114795,"twenty":-178.054894,"median":70.96482,"eighty":105.703373,"marketCap":1636336556},{"date":"2021-04-23","current":-164.142541,"twenty":-177.570402,"median":70.844418,"eighty":105.135102,"marketCap":1688041893},{"date":"2021-04-30","current":-168.180083,"twenty":-176.766636,"median":70.627694,"eighty":103.731578,"marketCap":1729563976},{"date":"2021-05-07","current":-146.959621,"twenty":-175.143647,"median":69.495918,"eighty":102.75377,"marketCap":1511332740},{"date":"2021-05-14","current":-91.341496,"twenty":-173.860714,"median":69.134713,"eighty":102.6761,"marketCap":1382362194},{"date":"2021-05-21","current":-95.480588,"twenty":-173.49996,"median":68.484543,"eighty":102.639567,"marketCap":1445003222},{"date":"2021-05-28","current":-99.222328,"twenty":-172.874456,"median":67.172163,"eighty":102.507152,"marketCap":1501630711},{"date":"2021-06-04","current":-104.801825,"twenty":-172.506749,"median":65.944065,"eighty":102.127511,"marketCap":1586070816},{"date":"2021-06-11","current":-119.023747,"twenty":-171.940864,"median":65.462458,"eighty":101.207424,"marketCap":1801305386},{"date":"2021-06-18","current":-121.623097,"twenty":-171.761303,"median":65.089212,"eighty":100.776014,"marketCap":1840643952},{"date":"2021-06-25","current":-121.490646,"twenty":-171.341217,"median":64.848409,"eighty":100.452102,"marketCap":1838639439},{"date":"2021-07-02","current":-117.450892,"twenty":-171.339369,"median":64.547404,"eighty":99.99422,"marketCap":1777501796},{"date":"2021-07-09","current":-121.507203,"twenty":-171.331975,"median":62.921979,"eighty":99.596394,"marketCap":1838890003},{"date":"2021-07-16","current":-107.599851,"twenty":-170.645651,"median":-30.05226,"eighty":99.432751,"marketCap":1628416150},{"date":"2021-07-23","current":-113.907828,"twenty":-170.627605,"median":-66.775802,"eighty":99.270596,"marketCap":1723881076},{"date":"2021-07-30","current":-115.646247,"twenty":-170.259225,"median":-79.533458,"eighty":98.781094,"marketCap":1750190308},{"date":"2021-08-06","current":-118.907852,"twenty":-170.259225,"median":-80.976934,"eighty":98.358362,"marketCap":1799551438},{"date":"2021-08-13","current":-71.922702,"twenty":-169.486373,"median":-79.89941,"eighty":97.576447,"marketCap":1621785000},{"date":"2021-08-20","current":-73.898232,"twenty":-168.830246,"median":-78.110313,"eighty":97.380969,"marketCap":1666331236},{"date":"2021-08-27","current":-82.916473,"twenty":-168.790806,"median":-79.533458,"eighty":97.12033,"marketCap":1869683545},{"date":"2021-09-03","current":-85.70677,"twenty":-168.558951,"median":-80.554542,"eighty":96.729373,"marketCap":1932601958},{"date":"2021-09-10","current":-83.128535,"twenty":-168.255857,"median":-81.000595,"eighty":96.620807,"marketCap":1874465345},{"date":"2021-09-17","current":-86.298313,"twenty":-167.864896,"median":-81.677581,"eighty":96.467657,"marketCap":1945940661},{"date":"2021-09-24","current":-80.851653,"twenty":-167.600615,"median":-81.817096,"eighty":96.094956,"marketCap":1823123920},{"date":"2021-10-01","current":-72.927209,"twenty":-167.548158,"median":-81.052554,"eighty":95.725323,"marketCap":1644435629},{"date":"2021-10-08","current":-68.418088,"twenty":-166.747019,"median":-80.939604,"eighty":95.341474,"marketCap":1542759474},{"date":"2021-10-15","current":-70.962839,"twenty":-166.488822,"median":-80.193143,"eighty":94.738911,"marketCap":1600141066},{"date":"2021-10-22","current":-70.014138,"twenty":-166.318802,"median":-79.455917,"eighty":94.477414,"marketCap":1578748806},{"date":"2021-10-29","current":-69.590013,"twenty":-165.92895,"median":-79.054701,"eighty":94.395866,"marketCap":1569185207},{"date":"2021-11-05","current":-66.46488,"twenty":-165.628697,"median":-75.845859,"eighty":94.279373,"marketCap":1498716585},{"date":"2021-11-12","current":-43.948833,"twenty":-165.400692,"median":-74.221907,"eighty":94.202941,"marketCap":1307521726},{"date":"2021-11-19","current":-40.394148,"twenty":-165.136289,"median":-73.228561,"eighty":94.032207,"marketCap":1201766292},{"date":"2021-11-26","current":-36.669382,"twenty":-164.802892,"median":-72.66492,"eighty":93.911867,"marketCap":1090950790},{"date":"2021-12-03","current":-35.232201,"twenty":-164.332488,"median":-72.525406,"eighty":93.857997,"marketCap":1048193210},{"date":"2021-12-10","current":-35.043363,"twenty":-164.069675,"median":-71.699478,"eighty":93.782419,"marketCap":1042575102},{"date":"2021-12-17","current":-36.565484,"twenty":-163.125113,"median":-70.962839,"eighty":93.656387,"marketCap":1087859706},{"date":"2021-12-23","current":-36.824936,"twenty":-162.260438,"median":-70.538714,"eighty":93.390391,"marketCap":1095578673},{"date":"2021-12-31","current":-37.07574,"twenty":-161.75254,"median":-70.326651,"eighty":93.033305,"marketCap":1103040341},{"date":"2022-01-07","current":-33.80664,"twenty":-160.853861,"median":-70.081106,"eighty":92.949516,"marketCap":1005781361},{"date":"2022-01-14","current":-31.297701,"twenty":-159.513129,"median":-69.768592,"eighty":92.804142,"marketCap":931137898},{"date":"2022-01-21","current":-28.661836,"twenty":-159.163373,"median":-69.221694,"eighty":92.613304,"marketCap":852718272},{"date":"2022-01-28","current":-32.764914,"twenty":-159.153657,"median":-68.462733,"eighty":92.417037,"marketCap":974788953},{"date":"2022-02-04","current":-36.620613,"twenty":-159.037071,"median":-68.077672,"eighty":92.363653,"marketCap":1089499863},{"date":"2022-02-11","current":-37.07272,"twenty":-158.52701,"median":-67.458226,"eighty":92.230539,"marketCap":1102950479},{"date":"2022-02-18","current":-33.933566,"twenty":-157.725045,"median":-66.676942,"eighty":92.12856,"marketCap":1009557525},{"date":"2022-02-25","current":-38.121947,"twenty":-157.70385,"median":-56.620469,"eighty":92.103044,"marketCap":1134166058},{"date":"2022-03-04","current":-34.317143,"twenty":-156.502465,"median":-46.976268,"eighty":91.895938,"marketCap":1073852040},{"date":"2022-03-11","current":-32.441312,"twenty":-155.908697,"median":-44.969316,"eighty":91.848137,"marketCap":1015153549},{"date":"2022-03-18","current":-36.6396,"twenty":-155.213239,"median":-44.561123,"eighty":91.680837,"marketCap":1146526362},{"date":"2022-03-25","current":-34.406468,"twenty":-154.956761,"median":-41.163763,"eighty":91.549188,"marketCap":1076647206},{"date":"2022-04-01","current":-37.337961,"twenty":-153.952054,"median":-39.575131,"eighty":91.549188,"marketCap":1168379479},{"date":"2022-04-08","current":-26.594568,"twenty":-153.917029,"median":-38.48489,"eighty":91.417935,"marketCap":832197215},{"date":"2022-04-14","current":-21.064522,"twenty":-153.883221,"median":-38.135515,"eighty":91.392618,"marketCap":659151015},{"date":"2022-04-22","current":-18.65924,"twenty":-153.705343,"median":-38.019584,"eighty":91.277765,"marketCap":583884947},{"date":"2022-04-29","current":-18.194999,"twenty":-153.646928,"median":-37.870138,"eighty":90.837881,"marketCap":569357910},{"date":"2022-05-06","current":-17.742098,"twenty":-153.581085,"median":-37.62719,"eighty":90.669444,"marketCap":555185744},{"date":"2022-05-13","current":-10.02426,"twenty":-153.127806,"median":-37.342022,"eighty":90.431678,"marketCap":517602654},{"date":"2022-05-20","current":-11.01092,"twenty":-152.745149,"median":-37.268917,"eighty":90.138886,"marketCap":568548831},{"date":"2022-05-27","current":-11.534765,"twenty":-152.15131,"median":-37.07423,"eighty":89.945688,"marketCap":595597574},{"date":"2022-06-03","current":-9.714021,"twenty":-151.992333,"median":-36.988631,"eighty":89.740147,"marketCap":501583495},{"date":"2022-06-10","current":-9.890877,"twenty":-151.80124,"median":-36.824936,"eighty":89.553726,"marketCap":510715451},{"date":"2022-06-17","current":-8.14483,"twenty":-151.608171,"median":-36.696416,"eighty":89.491586,"marketCap":420558272},{"date":"2022-06-24","current":-12.130705,"twenty":-151.344402,"median":-36.658551,"eighty":89.461816,"marketCap":626368976},{"date":"2022-07-01","current":-11.458757,"twenty":-150.793512,"median":-36.620613,"eighty":89.366342,"marketCap":591672918},{"date":"2022-07-08","current":-13.133538,"twenty":-150.278593,"median":-36.428467,"eighty":89.249147,"marketCap":678150213},{"date":"2022-07-15","current":-12.588852,"twenty":-149.603714,"median":-36.089951,"eighty":89.1582,"marketCap":650025379},{"date":"2022-07-22","current":-12.950279,"twenty":-149.104402,"median":-35.730106,"eighty":89.071615,"marketCap":668687652},{"date":"2022-07-29","current":-14.23309,"twenty":-147.282584,"median":-35.640177,"eighty":88.843853,"marketCap":734925580},{"date":"2022-08-05","current":-15.556624,"twenty":-147.050863,"median":-35.579565,"eighty":88.468661,"marketCap":803266299},{"date":"2022-08-12","current":-20.060215,"twenty":-146.936061,"median":-35.460837,"eighty":88.420861,"marketCap":892519093},{"date":"2022-08-19","current":-18.842653,"twenty":-146.702706,"median":-35.366658,"eighty":88.334821,"marketCap":838347339},{"date":"2022-08-26","current":-18.287067,"twenty":-146.099345,"median":-35.166981,"eighty":87.890279,"marketCap":813628189},{"date":"2022-09-02","current":-16.543472,"twenty":-145.861154,"median":-35.147161,"eighty":86.833894,"marketCap":736052134},{"date":"2022-09-09","current":-17.335478,"twenty":-145.658896,"median":-35.015504,"eighty":86.661813,"marketCap":771290071},{"date":"2022-09-16","current":-16.04699,"twenty":-144.832405,"median":-34.913637,"eighty":86.238683,"marketCap":713962681},{"date":"2022-09-23","current":-14.569367,"twenty":-144.059553,"median":-34.541755,"eighty":85.557518,"marketCap":648220261},{"date":"2022-09-30","current":-15.414567,"twenty":-143.904983,"median":-34.361806,"eighty":85.203906,"marketCap":685824925},{"date":"2022-10-07","current":-15.733734,"twenty":-143.10859,"median":-34.256358,"eighty":84.606403,"marketCap":700025288},{"date":"2022-10-14","current":-13.014907,"twenty":-142.900276,"median":-33.942644,"eighty":84.37758,"marketCap":579059235},{"date":"2022-10-21","current":-12.701651,"twenty":-142.591135,"median":-33.780695,"eighty":84.023258,"marketCap":565121842},{"date":"2022-10-28","current":-13.848286,"twenty":-141.740998,"median":-33.572754,"eighty":83.567141,"marketCap":616137960},{"date":"2022-11-04","current":-10.918859,"twenty":-139.963439,"median":-33.417462,"eighty":82.764196,"marketCap":578153577},{"date":"2022-11-11","current":-11.152763,"twenty":-139.808869,"median":-32.603113,"eighty":82.764196,"marketCap":590538818},{"date":"2022-11-18","current":-10.45105,"twenty":-139.422443,"median":-31.297701,"eighty":82.306669,"marketCap":553383096},{"date":"2022-11-25","current":-10.585421,"twenty":-137.629427,"median":-30.939428,"eighty":82.215327,"marketCap":560498021},{"date":"2022-12-02","current":-12.795071,"twenty":-137.051739,"median":-30.146712,"eighty":81.917812,"marketCap":677499018},{"date":"2022-12-09","current":-11.107973,"twenty":-132.017079,"median":-29.830488,"eighty":81.521649,"marketCap":588167176},{"date":"2022-12-16","current":-11.978894,"twenty":-129.220801,"median":-29.148408,"eighty":81.035226,"marketCap":634282434},{"date":"2022-12-23","current":-11.560852,"twenty":-127.462725,"median":-28.661836,"eighty":80.413953,"marketCap":612147110},{"date":"2022-12-30","current":-11.715129,"twenty":-126.444312,"median":-28.295032,"eighty":80.255022,"marketCap":620316099},{"date":"2023-01-06","current":-11.346854,"twenty":-125.431062,"median":-25.10852,"eighty":80.129804,"marketCap":600815932},{"date":"2023-01-13","current":-13.541575,"twenty":-124.480726,"median":-21.758823,"eighty":79.936775,"marketCap":717026382},{"date":"2023-01-20","current":-13.257903,"twenty":-124.252248,"median":-20.468425,"eighty":79.81117,"marketCap":702005984},{"date":"2023-01-27","current":-12.939395,"twenty":-123.914499,"median":-20.219799,"eighty":79.508532,"marketCap":685140976},{"date":"2023-02-03","current":-14.084034,"twenty":-123.669464,"median":-19.981754,"eighty":79.275321,"marketCap":745749600},{"date":"2023-02-10","current":-13.1733,"twenty":-123.391317,"median":-19.773366,"eighty":78.392678,"marketCap":697526216},{"date":"2023-02-17","current":-12.939395,"twenty":-122.237123,"median":-19.352035,"eighty":78.237088,"marketCap":685140976},{"date":"2023-02-24","current":-12.123218,"twenty":-121.646854,"median":-19.194328,"eighty":78.044446,"marketCap":641924391},{"date":"2023-03-03","current":-9.769225,"twenty":-121.623097,"median":-18.990416,"eighty":77.996285,"marketCap":655886202},{"date":"2023-03-10","current":-7.706921,"twenty":-121.507203,"median":-18.763163,"eighty":77.67537,"marketCap":517427243},{"date":"2023-03-17","current":-8.470884,"twenty":-121.490646,"median":-18.651096,"eighty":77.514678,"marketCap":568718182},{"date":"2023-03-24","current":-8.910261,"twenty":-121.407864,"median":-18.327158,"eighty":77.346115,"marketCap":598217116},{"date":"2023-03-31","current":-8.993387,"twenty":-120.530377,"median":-18.243867,"eighty":76.98491,"marketCap":603797995},{"date":"2023-04-06","current":-8.827136,"twenty":-120.25223,"median":-18.109752,"eighty":76.792267,"marketCap":592636236},{"date":"2023-04-14","current":-9.233586,"twenty":-119.573419,"median":-17.654644,"eighty":76.705578,"marketCap":619924514},{"date":"2023-04-21","current":-9.5476,"twenty":-119.262158,"median":-17.35912,"eighty":76.599624,"marketCap":641006751},{"date":"2023-04-28","current":-8.804302,"twenty":-119.063482,"median":-17.187715,"eighty":76.440694,"marketCap":591103228},{"date":"2023-05-05","current":-8.18984,"twenty":-118.984012,"median":-16.797623,"eighty":75.90611,"marketCap":587367135},{"date":"2023-05-12","current":-8.442866,"twenty":-118.921097,"median":-16.759205,"eighty":75.624254,"marketCap":605513871},{"date":"2023-05-19","current":-8.747984,"twenty":-118.854872,"median":-16.543472,"eighty":75.272328,"marketCap":627396699},{"date":"2023-05-26","current":-9.369385,"twenty":-118.099901,"median":-16.162244,"eighty":74.854441,"marketCap":671962947},{"date":"2023-06-02","current":-7.832628,"twenty":-117.894602,"median":-15.796084,"eighty":74.668379,"marketCap":561748214},{"date":"2023-06-09","current":-5.33214,"twenty":-117.642945,"median":-15.68645,"eighty":74.514265,"marketCap":382415768},{"date":"2023-06-16","current":-4.986091,"twenty":-117.464137,"median":-15.580163,"eighty":74.456472,"marketCap":357597438},{"date":"2023-06-23","current":-4.930276,"twenty":-117.424402,"median":-15.417523,"eighty":74.456472,"marketCap":353594482},{"date":"2023-06-30","current":-4.933997,"twenty":-117.219102,"median":-15.257939,"eighty":74.432392,"marketCap":353861345},{"date":"2023-07-07","current":-4.941439,"twenty":-116.556848,"median":-15.108846,"eighty":74.33607,"marketCap":354395073},{"date":"2023-07-14","current":-6.02796,"twenty":-116.507179,"median":-14.859223,"eighty":74.263829,"marketCap":432319291},{"date":"2023-07-21","current":-6.214009,"twenty":-115.646247,"median":-14.557546,"eighty":74.167508,"marketCap":445662479},{"date":"2023-07-28","current":-5.894006,"twenty":-115.613135,"median":-14.258542,"eighty":74.167508,"marketCap":422712195},{"date":"2023-08-04","current":-5.663815,"twenty":-115.513796,"median":-14.240825,"eighty":73.926704,"marketCap":503218594},{"date":"2023-08-11","current":-5.280594,"twenty":-114.553527,"median":-14.178591,"eighty":73.01165,"marketCap":469170240},{"date":"2023-08-18","current":-5.208175,"twenty":-113.907828,"median":-14.052198,"eighty":72.867168,"marketCap":462735905},{"date":"2023-08-25","current":-5.64571,"twenty":-113.791934,"median":-13.89557,"eighty":72.843088,"marketCap":501610010},{"date":"2023-09-01","current":-6.013843,"twenty":-113.659483,"median":-13.834522,"eighty":72.3374,"marketCap":534317879},{"date":"2023-09-08","current":-5.66985,"twenty":-113.552925,"median":-13.793063,"eighty":72.260343,"marketCap":503754789},{"date":"2023-09-15","current":-5.310769,"twenty":-113.447412,"median":-13.581503,"eighty":72.241079,"marketCap":471851212},{"date":"2023-09-22","current":-5.027126,"twenty":-113.123056,"median":-13.47439,"eighty":72.241079,"marketCap":446650068},{"date":"2023-09-29","current":-5.247402,"twenty":-111.576691,"median":-13.437064,"eighty":72.20255,"marketCap":466221169},{"date":"2023-10-06","current":-4.483979,"twenty":-111.103179,"median":-13.330065,"eighty":72.115861,"marketCap":398392558},{"date":"2023-10-13","current":-3.678311,"twenty":-110.692581,"median":-13.257903,"eighty":72.096597,"marketCap":326810584},{"date":"2023-10-20","current":-3.862378,"twenty":-109.828339,"median":-13.190718,"eighty":72.058068,"marketCap":343164518},{"date":"2023-10-27","current":-3.946867,"twenty":-109.228998,"median":-13.161054,"eighty":72.033988,"marketCap":350671242},{"date":"2023-11-03","current":-5.912031,"twenty":-107.583295,"median":-13.139027,"eighty":71.942483,"marketCap":446381971},{"date":"2023-11-10","current":-6.105341,"twenty":-107.470712,"median":-13.073766,"eighty":71.720944,"marketCap":460977687},{"date":"2023-11-17","current":-6.860935,"twenty":-106.821702,"median":-13.014907,"eighty":71.306761,"marketCap":518028049},{"date":"2023-11-24","current":-7.085475,"twenty":-104.967388,"median":-12.997175,"eighty":71.037061,"marketCap":534981694},{"date":"2023-12-01","current":-7.12468,"twenty":-104.801825,"median":-12.950279,"eighty":70.892579,"marketCap":537941854},{"date":"2023-12-08","current":-6.878756,"twenty":-104.621466,"median":-12.939395,"eighty":70.868499,"marketCap":519373576},{"date":"2023-12-15","current":-7.345656,"twenty":-102.303773,"median":-12.93329,"eighty":70.844418,"marketCap":554626394},{"date":"2023-12-22","current":-7.766222,"twenty":-101.653193,"median":-12.899374,"eighty":70.675856,"marketCap":586380840},{"date":"2023-12-29","current":-7.994326,"twenty":-101.138387,"median":-12.831107,"eighty":70.661407,"marketCap":603603591},{"date":"2024-01-05","current":-7.242296,"twenty":-100.480612,"median":-12.765211,"eighty":70.642143,"marketCap":546822335},{"date":"2024-01-12","current":-7.345656,"twenty":-99.17597,"median":-12.686153,"eighty":70.492844,"marketCap":554626394},{"date":"2024-01-19","current":-6.957166,"twenty":-98.990539,"median":-12.535401,"eighty":70.049766,"marketCap":525293896},{"date":"2024-01-26","current":-7.356348,"twenty":-98.377953,"median":-12.367076,"eighty":69.495918,"marketCap":555433710},{"date":"2024-02-02","current":-8.439841,"twenty":-98.245502,"median":-12.314821,"eighty":69.375516,"marketCap":637241776},{"date":"2024-02-09","current":-8.500431,"twenty":-97.897818,"median":-12.148101,"eighty":69.255114,"marketCap":641816569},{"date":"2024-02-16","current":-8.867536,"twenty":-97.587065,"median":-12.126962,"eighty":69.014311,"marketCap":669534434},{"date":"2024-02-23","current":-8.682202,"twenty":-97.554536,"median":-12.050186,"eighty":68.879461,"marketCap":655540949},{"date":"2024-03-01","current":-8.626783,"twenty":-97.496408,"median":-11.968941,"eighty":68.556784,"marketCap":495746692},{"date":"2024-03-08","current":-9.911724,"twenty":-97.444174,"median":-11.921994,"eighty":68.446014,"marketCap":569587147},{"date":"2024-03-15","current":-9.219098,"twenty":-97.381259,"median":-11.8495,"eighty":67.954775,"marketCap":529784671},{"date":"2024-03-22","current":-10.07891,"twenty":-97.328279,"median":-11.779827,"eighty":66.774837,"marketCap":579194641},{"date":"2024-03-28","current":-10.164891,"twenty":-96.980595,"median":-11.747478,"eighty":66.394368,"marketCap":584135638},{"date":"2024-04-05","current":-10.145784,"twenty":-96.034573,"median":-11.715129,"eighty":65.869416,"marketCap":583037638},{"date":"2024-04-12","current":-9.975623,"twenty":-95.509954,"median":-11.674233,"eighty":65.541923,"marketCap":573259148},{"date":"2024-04-19","current":-9.21713,"twenty":-93.841259,"median":-11.590712,"eighty":65.486538,"marketCap":529671590},{"date":"2024-04-26","current":-9.365948,"twenty":-92.601993,"median":-11.540343,"eighty":65.296304,"marketCap":538223579},{"date":"2024-05-03","current":-20.460076,"twenty":-92.472226,"median":-11.516062,"eighty":65.156637,"marketCap":630088496},{"date":"2024-05-10","current":-21.891395,"twenty":-91.785206,"median":-11.553387,"eighty":65.07958,"marketCap":674167408},{"date":"2024-05-17","current":-21.712105,"twenty":-90.954077,"median":-11.630526,"eighty":64.939914,"marketCap":668645972},{"date":"2024-05-24","current":-21.281807,"twenty":-90.477253,"median":-11.705647,"eighty":64.858041,"marketCap":655394524},{"date":"2024-05-31","current":-21.70314,"twenty":-90.243501,"median":-11.725082,"eighty":64.752087,"marketCap":668369900},{"date":"2024-06-07","current":-20.645325,"twenty":-89.767451,"median":-11.754943,"eighty":64.597973,"marketCap":635793424},{"date":"2024-06-14","current":-20.331566,"twenty":-89.137652,"median":-11.784803,"eighty":64.569077,"marketCap":626130910},{"date":"2024-06-21","current":-18.888276,"twenty":-88.682246,"median":-11.8495,"eighty":64.511283,"marketCap":581683345},{"date":"2024-06-28","current":-18.968957,"twenty":-88.19431,"median":-11.87936,"eighty":63.91409,"marketCap":584167992},{"date":"2024-07-05","current":-19.049638,"twenty":-87.429878,"median":-11.962718,"eighty":62.979772,"marketCap":586652638},{"date":"2024-07-12","current":-16.575426,"twenty":-87.283498,"median":-11.973917,"eighty":62.661912,"marketCap":510456813},{"date":"2024-07-15","current":-16.629213,"twenty":-87.267233,"median":-11.978894,"eighty":62.498165,"marketCap":512113244},{"date":"2024-08-02","current":-20.654289,"twenty":-86.610826,"median":-11.921994,"eighty":63.018301,"marketCap":636069496},{"date":"2024-08-09","current":-249.174378,"twenty":-87.299762,"median":-11.921994,"eighty":63.018301,"marketCap":772191398},{"date":"2024-08-16","current":-242.909218,"twenty":-92.450772,"median":-11.921994,"eighty":63.018301,"marketCap":752775666},{"date":"2024-08-23","current":-246.399807,"twenty":-97.318345,"median":-11.921994,"eighty":63.018301,"marketCap":763593002},{"date":"2024-08-30","current":-266.627325,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":826278080},{"date":"2024-09-06","current":-263.852754,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":817679684},{"date":"2024-09-13","current":-274.593029,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":850963796},{"date":"2024-09-20","current":-273.250494,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":846803282},{"date":"2024-09-27","current":-250.606415,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":776629280},{"date":"2024-10-04","current":-254.365511,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":788278719},{"date":"2024-10-11","current":-253.291484,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":784950308},{"date":"2024-10-18","current":-295.894574,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":916977285},{"date":"2024-10-25","current":-284.617286,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":882028968},{"date":"2024-10-31","current":-309.140913,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":958027690},{"date":"2024-11-08","current":153.567604,"twenty":-91.563351,"median":-11.784803,"eighty":64.853225,"marketCap":932923196},{"date":"2024-11-15","current":142.134171,"twenty":-90.404405,"median":-11.754943,"eighty":65.240919,"marketCap":863465089},{"date":"2024-11-22","current":133.144173,"twenty":-90.404405,"median":-11.754943,"eighty":65.474498,"marketCap":808850852},{"date":"2024-11-29","current":139.598531,"twenty":-90.404405,"median":-11.754943,"eighty":66.977112,"marketCap":848061074},{"date":"2024-12-06","current":148.265811,"twenty":-90.404405,"median":-11.754943,"eighty":69.332172,"marketCap":900714800},{"date":"2024-12-13","current":134.250635,"twenty":-90.404405,"median":-11.754943,"eighty":70.85405,"marketCap":815572605},{"date":"2024-12-20","current":124.891816,"twenty":-90.404405,"median":-11.754943,"eighty":71.990643,"marketCap":758717784},{"date":"2024-12-27","current":124.937919,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":758997857},{"date":"2025-01-03","current":129.271559,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":785324720},{"date":"2025-01-10","current":150.847554,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":916398888},{"date":"2025-01-17","current":115.671306,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":702703182},{"date":"2025-01-24","current":122.171766,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":742193476},{"date":"2025-01-31","current":130.101405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":790366034},{"date":"2025-02-07","current":128.303405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":779443186},{"date":"2025-02-14","current":127.289149,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":773281580},{"date":"2025-02-21","current":120.558176,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":732390921},{"date":"2025-02-28","current":38.806499,"twenty":-90.477253,"median":-11.764897,"eighty":76.356928,"marketCap":708024569},{"date":"2025-03-07","current":32.178981,"twenty":-90.550101,"median":-11.77485,"eighty":73.454249,"marketCap":587105504},{"date":"2025-03-14","current":29.318974,"twenty":-90.550101,"median":-11.77485,"eighty":33.288601,"marketCap":534924684},{"date":"2025-03-21","current":31.366301,"twenty":-90.550101,"median":-11.77485,"eighty":31.49758,"marketCap":572278167},{"date":"2025-03-28","current":31.413187,"twenty":-90.550101,"median":-11.77485,"eighty":31.375678,"marketCap":573133590},{"date":"2025-04-04","current":29.990998,"twenty":-90.550101,"median":-11.77485,"eighty":31.063109,"marketCap":547185751},{"date":"2025-04-11","current":30.162911,"twenty":-90.477253,"median":-11.764897,"eighty":30.312944,"marketCap":550322303},{"date":"2025-04-17","current":33.226087,"twenty":-90.477253,"median":-11.764897,"eighty":30.312944,"marketCap":606209957},{"date":"2025-04-25","current":33.089862,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"marketCap":603724531},{"date":"2025-05-02","current":30.528678,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"marketCap":556995733},{"date":"2025-05-09","current":-98.025753,"twenty":-95.154431,"median":-11.87936,"eighty":29.478384,"marketCap":496892541},{"date":"2025-05-16","current":-93.867775,"twenty":-96.90247,"median":-11.978894,"eighty":-3.786337,"marketCap":475815751},{"date":"2025-05-23","current":-90.507217,"twenty":-96.90247,"median":-12.148101,"eighty":-3.979456,"marketCap":458781085},{"date":"2025-05-30","current":-90.848969,"twenty":-96.90247,"median":-12.322286,"eighty":-4.309569,"marketCap":460513424},{"date":"2025-06-06","current":-96.943539,"twenty":-96.977714,"median":-12.588852,"eighty":-4.550363,"marketCap":491406801},{"date":"2025-06-13","current":-107.196088,"twenty":-97.40775,"median":-12.795071,"eighty":-4.74909,"marketCap":543376968},{"date":"2025-06-17","current":-109.759225,"twenty":-97.732254,"median":-12.899374,"eighty":-4.847918,"marketCap":556369510}],"updateTime":1750288619058}}}